research Pantolactams as androgen receptor antagonists for the topical suppression of sebum production
Pfizer found that pantolactam-based compounds can reduce sebum (skin oil) production when applied topically.
Search
for
Sort by
Research
450-480 / 1000+ results research Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review
GLP-1 receptor agonists help women with PCOS lose weight and improve health, but more research is needed on long-term effects.
research Agouti and Agouti-related Protein: Analogies and Contrasts
Agouti and AGRP affect pigmentation and obesity, with implications for metabolic disorders.
research “From evidence to practice” – Insights from the multidisciplinary team on the optimal integration of GLP ‐1 receptor agonists in obesity management services
GLP-1 receptor agonists help with weight loss but need to be combined with other treatments for best results.
research Androgen receptor modulators: a review of recent patents and reports (2012-2018)
New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.
research Abstract 5561: 20(S)-Protopanaxadiol-aglycone downregulates full-length and ligand-independent splice variants of androgen receptor
20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.
research The use of a retinoid receptor antagonist in a new model to study vitamin A-dependent developmental events.
The retinoid receptor antagonist effectively disrupts vitamin A-related development in embryos.
research Glucocorticoid Receptor Antagonism Improves Glucose Metabolism in a Mouse Model of Polycystic Ovary Syndrome
Blocking glucocorticoid receptors improves glucose metabolism in a PCOS mouse model.
research Design, Synthesis, and Biological Characterization of Metabolically Stable Selective Androgen Receptor Modulators
Researchers developed new compounds that target the androgen receptor effectively with fewer side effects.
research Effects of GLP ‐1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review
GLP-1 receptor agonists may cause hair loss, but regrowth is rare.
research Androgen Receptor Ligands: Agonists and Antagonists
Different substances that activate or block the androgen receptor can affect male development and treat conditions like prostate cancer.
research Allopregnanolone is required for prepulse inhibition deficits induced by D1 dopamine receptor activation
Allopregnanolone is needed for certain brain processing issues caused by D1 dopamine receptor activation.
research Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development
The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
research Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
LGD1069 effectively prevents breast tumors in mice without toxicity.
research Selective androgen receptor modulators: a critical appraisal
SARMs show promise but need more evidence to prove they're better than traditional androgens.
research Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review
GLP-1 receptor agonists may cause hair loss, but more research is needed.
research Therapeutic Strategies to Target the Androgen Receptor
Therapies targeting the androgen receptor are being developed to treat prostate cancer and improve bone and muscle health.
research The prolactin receptor as a therapeutic target in human diseases: browsing new potential indications
Blocking the prolactin receptor might help treat various diseases, but more research is needed.
research Exploring the Role of GLP ‐1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review
GLP-1 receptor agonists may help manage and prevent diabetic foot ulcers.
research Therapeutic anti-inflammatory potential of formyl-peptide receptor agonists
Formyl-peptide receptor agonists could be new anti-inflammatory drugs.
research Androgen antagonists in androgen target tissues
Antiandrogens have important biological effects, but more research is needed to understand them fully and compare their effectiveness and side effects to other treatments.
research Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review
GLP-1 agonists may help treat certain skin conditions.
research GLP-1 RAs and Skin Health: Exploring Dermatologic Side Effects and Therapeutic Interventions
GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.
research Allopregnanolone (AP) induces opioid inhibition of hypothalamo-pituitary-adrenal (HPA) axis responses to interleukin-1β (IL-1β) in pregnancy
Allopregnanolone and opioids together reduce stress hormone responses during pregnancy.
research Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation
Breast cancer treatments work better with AR activation, improving results and reducing side effects.
research 570 Targeting phosphodiesterase 8A (PDE8A) to boost adipogenesis and hair regeneration
Inhibiting PDE8A may help treat hair loss by boosting fat cell growth and hair regeneration.
research Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review
GLP-1 receptor agonists for weight loss may cause hair loss, especially in women.
research Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database
GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
![Discovery of (2S)-N-(6-Cyano-5-(Trifluoromethyl)Pyridin-3-Yl)-3-(6-(4-Cyanophenyl)-3,6-Diazabicyclo[3.1.1]Heptan-3-Yl)-2-Hydroxy-2-Methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment](/images/research/693e7bf6-2325-4ddc-a20f-3470db9f4516/small/25627.jpg)
research Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment
A new topical treatment for hair loss shows strong hair growth effects with low toxicity.
research Parathyroid hormone-related peptide and the hair cycle - is it the agonists or the antagonists that cause hair growth?
PTHRP agonists can stimulate hair growth, especially in damaged follicles, while antagonists may initially increase growth but ultimately inhibit it.